You are here: Home: Meet The Professors Vol. 1 2003: Case 3: Select publications

 

Select publications:
Recent clinical trial data regarding taxane use in the metastatic setting

Aihara T et al. Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer. Oncology 2003;64(2):124-30. Abstract.

Aihara T et al. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002;13(2):286-92. Abstract.

Alba E et al. Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: A GEICAM-9801 phase II study. Breast Cancer Res Treat 2003;77(1):1-8. Abstract.

Baltali E et al. Paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast cancer. Tumori 2002;88(3):200-3. Abstract.

Biganzoli L et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002;20(14):3114-21. Abstract.

Gennari A et al. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. Clin Breast Cancer 2002;3(5):346-52. Abstract.

Gori S et al. Weekly paclitaxel in metastatic breast cancer patients: A phase II study. Tumori 2002;88(6):470-3. Abstract.

Loesch D et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002;20(18):3857-64. Abstract.

Mavroudis D et al. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial. Oncology 2003;64(3):207-12. Abstract.

Nabholtz JM et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21(6):968-75. Abstract.

O'Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract.

Perez EA et al. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol 2002;13(8):1225-35. Abstract.

Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract.

Smith RE et al. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: Results from NSABP trial BP-58. Clin Breast Cancer. 2002;3(5):333-40. Abstract.

Talbot DC et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86(9):1367-72. Abstract.

Venturini M et al. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer 2003;97(5):1174-80. Abstract.

 

 

Table of Contents Top of Page 

 

Home · Search

 
CME Information
Faculty
Editor's Note
 
CASE 1: Disease recurrence and brachial plexopathy during the third trimester of pregnancy
- Select publications
 
CASE 2: Unresectable local recurrence in the pectoralis major after breast-conserving
surgery
- Select publications
 
CASE 3: Pulmonary metastases and mild shortness of breath
- Select publications
 
CASE 4: HER2-positive metastases to the lung and residual local breast cancer after lumpectomy
- Select publications
 
CASE 5: Liver metastases and mild hepatic encephalopathy
- Select publications
 
CASE 6: Ascites and pleural effusion ten years after primary breast cancer
- Select publications
Home · Contact us
Terms of use and general disclaimer